U.S. markets closed
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • Dow 30

    31,029.31
    +82.32 (+0.27%)
     
  • Nasdaq

    11,177.89
    -3.65 (-0.03%)
     
  • Russell 2000

    1,719.37
    -19.47 (-1.12%)
     
  • Crude Oil

    109.52
    -2.24 (-2.00%)
     
  • Gold

    1,819.60
    -1.60 (-0.09%)
     
  • Silver

    20.73
    -0.14 (-0.68%)
     
  • EUR/USD

    1.0445
    -0.0080 (-0.76%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • GBP/USD

    1.2125
    -0.0060 (-0.49%)
     
  • USD/JPY

    136.6090
    +0.4810 (+0.35%)
     
  • BTC-USD

    20,151.43
    -133.58 (-0.66%)
     
  • CMC Crypto 200

    434.46
    -5.20 (-1.18%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens.

  • With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a longer runway, RBC Capital continues to like the VSTM setup.

  • The company plans to complete enrollment of all four trial cohorts in the second half of this year.

  • Related: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.

  • It has reiterated the Outperform, Speculative Risk rating, and a price target of $5.

  • RBC Capitals believes VSTM has exhibited differentiating safety profile exhibited thus far, all of which it finds reassuring.

  • The analysts noted that around 6% had discontinued the trial based on treatment-related adverse events compared to ~30% for tyrosine kinase inhibitors' current standard of care.

  • However, the update has generated interest in the clarity around the planned regulatory interactions, which are still pending and will guide go-forward dosing and trial design.

  • Price Action: VSTM shares are up 6.15% at $1.30 during the market session on the last check Tuesday.

Latest Ratings for VSTM

Date

Firm

Action

From

To

Mar 2022

Truist Securities

Initiates Coverage On

Buy

Jul 2021

HC Wainwright & Co.

Maintains

Buy

Jul 2021

Alliance Global Partners

Initiates Coverage On

Buy

View More Analyst Ratings for VSTM

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.